ARGNF
Price
$697.42
Change
+$72.12 (+11.53%)
Updated
Jan 29 closing price
Capitalization
36.36B
BLUE
Price
$5.26
Change
+$0.38 (+7.79%)
Updated
Apr 1, 04:59 PM (EDT)
Capitalization
47.78M
Ad is loading...

ARGNF vs BLUE

Header iconARGNF vs BLUE Comparison
Open Charts ARGNF vs BLUEBanner chart's image
Argen X
Price$697.42
Change+$72.12 (+11.53%)
Volume$1
Capitalization36.36B
bluebird bio
Price$5.26
Change+$0.38 (+7.79%)
Volume$8.55K
Capitalization47.78M
ARGNF vs BLUE Comparison Chart
Loading...
BLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARGNF vs. BLUE commentary
Apr 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARGNF is a Hold and BLUE is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 01, 2025
Stock price -- (ARGNF: $697.42 vs. BLUE: $4.88)
Brand notoriety: ARGNF and BLUE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARGNF: 47% vs. BLUE: 751%
Market capitalization -- ARGNF: $36.36B vs. BLUE: $47.78M
ARGNF [@Biotechnology] is valued at $36.36B. BLUE’s [@Biotechnology] market capitalization is $47.78M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.22B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARGNF’s FA Score shows that 1 FA rating(s) are green whileBLUE’s FA Score has 1 green FA rating(s).

  • ARGNF’s FA Score: 1 green, 4 red.
  • BLUE’s FA Score: 1 green, 4 red.
According to our system of comparison, ARGNF is a better buy in the long-term than BLUE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BLUE’s TA Score shows that 5 TA indicator(s) are bullish.

  • BLUE’s TA Score: 5 bullish, 3 bearish.

Price Growth

ARGNF (@Biotechnology) experienced а 0.00% price change this week, while BLUE (@Biotechnology) price change was +24.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.00%. For the same industry, the average monthly price growth was -12.26%, and the average quarterly price growth was -11.16%.

Reported Earning Dates

BLUE is expected to report earnings on Feb 25, 2025.

Industries' Descriptions

@Biotechnology (-8.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARGNF($36.4B) has a higher market cap than BLUE($47.8M). ARGNF YTD gains are higher at: 6.909 vs. BLUE (-41.487). ARGNF has higher annual earnings (EBITDA): -60.47M vs. BLUE (-215.81M). ARGNF has more cash in the bank: 3.1B vs. BLUE (70.7M). ARGNF has less debt than BLUE: ARGNF (34M) vs BLUE (368M). ARGNF has higher revenues than BLUE: ARGNF (1.86B) vs BLUE (53.1M).
ARGNFBLUEARGNF / BLUE
Capitalization36.4B47.8M76,151%
EBITDA-60.47M-215.81M28%
Gain YTD6.909-41.487-17%
P/E Ratio54.57N/A-
Revenue1.86B53.1M3,501%
Total Cash3.1B70.7M4,388%
Total Debt34M368M9%
FUNDAMENTALS RATINGS
ARGNF vs BLUE: Fundamental Ratings
ARGNF
BLUE
OUTLOOK RATING
1..100
4229
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
5100
SMR RATING
1..100
92100
PRICE GROWTH RATING
1..100
4065
P/E GROWTH RATING
1..100
44100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BLUE's Valuation (25) in the Biotechnology industry is somewhat better than the same rating for ARGNF (80) in the null industry. This means that BLUE’s stock grew somewhat faster than ARGNF’s over the last 12 months.

ARGNF's Profit vs Risk Rating (5) in the null industry is significantly better than the same rating for BLUE (100) in the Biotechnology industry. This means that ARGNF’s stock grew significantly faster than BLUE’s over the last 12 months.

ARGNF's SMR Rating (92) in the null industry is in the same range as BLUE (100) in the Biotechnology industry. This means that ARGNF’s stock grew similarly to BLUE’s over the last 12 months.

ARGNF's Price Growth Rating (40) in the null industry is in the same range as BLUE (65) in the Biotechnology industry. This means that ARGNF’s stock grew similarly to BLUE’s over the last 12 months.

ARGNF's P/E Growth Rating (44) in the null industry is somewhat better than the same rating for BLUE (100) in the Biotechnology industry. This means that ARGNF’s stock grew somewhat faster than BLUE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BLUE
RSI
ODDS (%)
Bullish Trend 2 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 7 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
86%
View a ticker or compare two or three
Ad is loading...
BLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IYT64.030.37
+0.58%
iShares Transportation Average ETF
FT7.530.03
+0.40%
Franklin Universal Trust
TYLG30.200.04
+0.14%
Global X Information Tch Cvd Cll&Gr ETF
ANGL28.860.03
+0.10%
VanEck Fallen Angel HiYld Bd ETF
MSTI20.46N/A
N/A
Madison Short-Term Strategic Income ETF

ARGNF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARGNF has been loosely correlated with ARGX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGNF jumps, then ARGX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARGNF
1D Price
Change %
ARGNF100%
N/A
ARGX - ARGNF
54%
Loosely correlated
+0.46%
BLUE - ARGNF
45%
Loosely correlated
+19.61%
MNKD - ARGNF
30%
Poorly correlated
N/A
TNXP - ARGNF
25%
Poorly correlated
-11.38%
ROIV - ARGNF
24%
Poorly correlated
-2.79%
More